NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SPRB

Spruce Biosciences Inc

May 16 • 03:55PM ET

0.0649

Dollar change -0.0010
Percentage change -1.52	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX BPMC VCYT AVXL IONS EXEL ACAD GERN ITCI ALDX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.33	Insider Own	11.73%	Shs Outstand	42.23M	Perf Week	-13.00%
Market Cap	2.74M	Forward P/E	-	EPS next Y	-1.20	Insider Trans	0.00%	Shs Float	25.00M	Perf Month	-47.24%
Income	-	PEG	-	EPS next Q	-0.15	Inst Own	41.35%	Short Float	2.05%	Perf Quarter	-84.00%
Sales	2.91M	P/S	0.94	EPS this Y	55.04%	Inst Trans	-	Short Ratio	0.35	Perf Half Y	-87.66%
Book/sh	0.36	P/B	0.18	EPS next Y	-106.03%	ROA	-	Short Interest	0.51M	Perf Year	-92.13%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.06 - 0.80	Perf YTD	-84.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-91.89%	Beta	2.38
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	13.86%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	-1.76%	Oper. Margin	-	RSI (14)	22.46	Volatility	15.44% 17.15%
Employees	20	Debt/Eq	-	Sales Y/Y TTM	-51.32%	Profit Margin	-	Recom	3.00	Target Price	-
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.06	Prev Close	0.07
Sales Surprise	-21.02%	EPS Surprise	-171.43%	Sales Q/Q	-	Earnings	Mar 12	Avg Volume	1.45M	Price	0.06
SMA20	-25.15%	SMA50	-69.35%	SMA200	-83.41%	Trades		Volume	91,932	Change	-1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-24	Downgrade	Oppenheimer	Outperform → Perform
Dec-11-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Mar-14-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$9 → $2
Mar-14-24	Downgrade	Leerink Partners	Outperform → Market Perform	$9 → $2
Mar-14-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-14-24	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-24	Downgrade	Guggenheim	Buy → Neutral
Feb-21-24	Initiated	Guggenheim	Buy	$10
Dec-17-21	Initiated	Oppenheimer	Outperform	$15
Dec-10-21	Initiated	The Benchmark Company	Speculative Buy	$7
Nov-16-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-19-21	Initiated	H.C. Wainwright	Buy	$30
Apr-26-21	Resumed	Credit Suisse	Outperform	$26
Nov-03-20	Initiated	SVB Leerink	Outperform	$35
Nov-03-20	Initiated	RBC Capital Mkts	Outperform	$28
Nov-03-20	Initiated	Credit Suisse	Outperform	$28
Nov-03-20	Initiated	Cowen	Outperform	$44

Show Previous Ratings

May-06-25 04:01PM	Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates (Business Wire)
Apr-15-25 05:27PM	Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript) (Seeking Alpha) -58.02% -6.82%
07:00AM	Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire)
Mar-20-25 09:25AM	Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Dec-13-24 12:00PM	Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why (Zacks)
08:21AM	Loading…
Dec-11-24 08:21AM	Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder (Benzinga) -20.02%
Dec-10-24 04:01PM	Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH (Business Wire)
Nov-12-24 10:59PM	Spruce Biosciences Reports Q3 2024 Earnings and Updates (TipRanks)
Nov-11-24 09:10AM	Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (Business Wire)
Oct-28-24 04:01PM	Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference (Business Wire)
Sep-03-24 04:01PM	Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-12-24 05:10PM	Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (Business Wire)
Jun-24-24 04:12AM	Pipeline Moves: Approval prospects for BioTissues diabetic foot ulcer drug up after Phase III completion (Clinical Trials Arena) +5.39%
08:00AM	Loading…
Jun-06-24 08:00AM	Spruce Biosciences Recognized as a Bay Area Best Place to Work (Business Wire) -6.74%
Jun-04-24 07:02AM	Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder (Benzinga)
07:00AM	Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD) (Business Wire)
Jun-03-24 07:00AM	Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024 (Business Wire)
May-23-24 04:05PM	Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-22-24 04:14PM	Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society (Business Wire)
May-13-24 08:55PM	SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates (Business Wire)
May-01-24 04:05PM	Spruce Biosciences to Participate in May Investor Conferences (Business Wire)
Apr-30-24 04:05PM	Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting (Business Wire)
Apr-22-24 04:05PM	Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting (Business Wire)
Mar-27-24 12:00PM	Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know (Zacks) +5.71%
Mar-21-24 10:20AM	Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why (Zacks)
Mar-14-24 08:28AM	Why Is Spruce Biosciences (SPRB) Stock Down 78% Today? (InvestorPlace) -84.38%
05:33PM	Loading…
Mar-13-24 05:33PM	Spruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial Setbacks (GuruFocus.com)
04:08PM	Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates (Business Wire)
04:01PM	Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH (Business Wire)
Jan-30-24 04:05PM	Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +6.71%
Jan-22-24 08:00AM	Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia (Business Wire)
Jan-05-24 08:00AM	Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH (Business Wire)
Jan-04-24 08:00AM	Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024 (Business Wire) +5.49%
Nov-13-23 04:05PM	Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (Business Wire)
Nov-02-23 04:05PM	Spruce Biosciences to Participate in the Jefferies London Healthcare Conference (Business Wire)
Oct-18-23 08:00AM	Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia (Business Wire) -12.97%
Aug-28-23 04:00PM	Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-14-23 04:00PM	Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (Business Wire)
Jul-24-23 12:00PM	Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why (Zacks)
Jun-12-23 04:00PM	Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023) (Business Wire)
May-25-23 08:00AM	Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors (Business Wire) -13.08%
May-24-23 04:05PM	Spruce Biosciences to Participate in the Jefferies Healthcare Conference (Business Wire) +6.12%
May-22-23 09:30AM	Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES Gala (Business Wire) +5.58%
May-16-23 06:18AM	Investors in Spruce Biosciences (NASDAQ:SPRB) have seen decent returns of 63% over the past year (Simply Wall St.)
May-15-23 08:00AM	Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates (Business Wire)
May-04-23 04:05PM	Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting (Business Wire) +7.31%
May-02-23 04:05PM	Spruce Biosciences to Participate in May Investor Conferences (Business Wire) +5.80%
Mar-31-23 12:00PM	Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-16-23 04:00PM	Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates (Business Wire)
Feb-28-23 04:05PM	Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
Feb-23-23 10:43AM	2 Strong Buy Penny Stocks With Multibagger Potential (TipRanks)
Feb-10-23 08:00AM	Eyeing treatment of hormonal disorder, Peninsula company lays $53 million PIPE (American City Business Journals) -7.33%
Feb-09-23 08:00AM	Spruce Biosciences Announces $53.6 Million Private Placement Financing (Business Wire) -5.36%
Feb-01-23 04:05PM	Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference (Business Wire)
Jan-31-23 09:55AM	Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy? (Zacks) +8.46%
Jan-09-23 08:05AM	Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 (Business Wire)
Jan-06-23 05:54PM	Two Covid-era biotech IPOs Spruce and Graphite Bio see stock head in different directions (American City Business Journals) +93.60%
06:16AM	Spruce Biosciences Shares Skyrocket After Licensing Pact For Lead Program (Benzinga)
Jan-05-23 04:00PM	Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan (Business Wire)
Nov-16-22 01:13PM	JMP Says Forgotten Spruce Biosciences Could Draw Attention In 2023 (Benzinga) +13.33%
Nov-10-22 04:01PM	Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates (Business Wire) +6.06% +10.48%
Oct-26-22 04:05PM	Spruce Biosciences to Participate in November Investor Conferences (Business Wire)
Aug-30-22 04:05PM	Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (Business Wire)
Aug-10-22 04:05PM	Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update (Business Wire)
Jun-01-22 04:01PM	Spruce Biosciences to Participate in June Investor Conferences (Business Wire) -6.41% +20.55%
May-31-22 08:00AM	Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference (Business Wire) +9.86%
May-11-22 04:01PM	Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update (Business Wire) -10.49%
May-03-22 04:05PM	Spruce Biosciences to Participate in May Investor Conferences (Business Wire)
Apr-11-22 08:00AM	Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer (Business Wire) -5.47%
Mar-14-22 04:05PM	Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates (Business Wire)
04:01PM	Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer (Business Wire)
Mar-01-22 04:05PM	Spruce Biosciences to Participate in March Investor Conferences (Business Wire) -7.05%
Feb-03-22 04:05PM	Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference (Business Wire)
Jan-24-22 08:00AM	Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022 (Business Wire)
Jan-19-22 09:38PM	Marquette Asset Management, LLC Buys Vanguard Total Bond Market ETF, ARK Next Generation ... (GuruFocus.com) -10.10% -5.80%
Jan-05-22 08:00AM	Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer (Business Wire) -15.64%
Dec-31-21 01:50PM	5 Beaten-Down Biotech Bets to Bounce Back in 2022 (Zacks) -11.16%
Dec-17-21 07:27AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +102.82%
07:16AM	Spruce Biosciences Rallies on Oppenheimer Outperform Rating (Investing.com)
Dec-14-21 10:00AM	Spruce Biosciences, Inc. (SPRB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-18-21 04:05PM	Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference (Business Wire) -5.47%
Nov-15-21 04:05PM	Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates (Business Wire) -29.76%
04:01PM	Spruce Biosciences Appoints Mike Grey as Interim CEO (Business Wire)
Sep-29-21 01:06PM	Spruce Biosciences, Inc. (SPRB): Are Hedge Funds Right About This Stock? (Insider Monkey)
Sep-07-21 04:05PM	Spruce Biosciences to Participate in September Investor Conferences (Business Wire)
Aug-25-21 09:00AM	Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day (Business Wire)
Aug-11-21 08:55AM	Spruce Biosciences Expands Tildacerfont Portfolio with Potential Treatment for Polycystic Ovary Syndrome (Benzinga)
Aug-10-21 04:05PM	Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates (Business Wire)
11:59AM	Why Earnings Season Could Be Great for Spruce Biosciences (SPRB) (Zacks)
Jul-23-21 10:14AM	2 Strong Buy Stocks Under $10 With Strong Growth Prospects (TipRanks)
Jul-07-21 11:38AM	Tildacerfont: New Drug Provides Hope, Treatments After 50-Year-Long Drought (Benzinga)
Jun-24-21 08:07AM	Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors (Benzinga)
Jun-21-21 08:03AM	Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism (Business Wire) -12.38%
May-24-21 08:01AM	Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology (Business Wire) -5.71%
May-13-21 04:05PM	Spruce Biosciences to Participate in the RBC Capital Markets Global Healthcare Conference (Business Wire)
May-12-21 04:05PM	Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates (Business Wire)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for neurological disorders. The company is engaged in developing tildacerfont, a non-steroidal therapy designed to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). This therapy is currently in Phase 2b clinical trials to evaluate glucocorticoid reduction in adult patients with classic CAH. Additionally, the company is developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children, which is in Phase 2 clinical trials. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses, as well as a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Charlton Ralph William III	CHIEF MEDICAL OFFICER	Dec 16 '24	Option Exercise	58,350	172,668	Dec 20 08:30 PM
Charlton Ralph William III	CHIEF MEDICAL OFFICER	Dec 10 '24	Option Exercise	106,400	161,773	Dec 20 08:30 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 16 '24	Option Exercise	75,750	363,841	Dec 20 08:28 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 10 '24	Option Exercise	154,000	356,776	Dec 20 08:28 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 16 '24	Option Exercise	200,700	506,796	Dec 20 08:28 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 10 '24	Option Exercise	358,800	466,121	Dec 20 08:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRB

Spruce Biosciences Inc

Upgrade your FINVIZ experience